CEO SUMMARY: Will 2015 turn out to be a watershed year for the clinical laboratory industry? Not only are two federal agencies pushing forward with initiatives that will touch nearly every medical lab in the United States in the next 12 months, but other equally powerful trends continue to negatively influence the prices labs are paid for their testing services. All these factors make it essential for lab administrators and pathologist business leaders to work proactively to maintain their lab’s financial stability.
Lab Industry to Confront Major Issues during 2015
Topping the list are FDA regulation of LDTs and PAMA’s market price reporting requirements
- By Robert Michel
- | From the Volume XXII No. 1 - January 5, 2015 Issue
- Tags: affordable care act, Anatomic pathology, Bundled payment, care contracts, clia, clia lab, clia labs, clia quality control, clinical lab, clinical lab test, clinical laboratories, Clinical Laboratory, clinical laboratory industry, clinical laboratory test, clinical laboratory testing, clinical labs, cpt, cpt code, CPT® codes, Fee-for-service, Histology, histology lab, histology laboratory, hospital lab outreach programs, impac, lab administrator, lab compliance, lab outreach, lab test, lab test prices, lab tests, laboratories, laboratory industry, laboratory medicine, laboratory test, laboratory testing, ldt, managed care, managed care contract, managed care contracts, managed care plan, managed care plans, medical lab, Medicare, Medicare Part B, pathologists, Pathology group, pathology groups, private payer, Protecting Access to Medicare Act (PAMA), quality control, quality control plan, the affordable care act, the clinical laboratory
